<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 REPORTING REQUIREMENTS
FORM 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 19, 2000
--------------------------------
KING PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Tennessee 0--24425 54-1684963
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
501 Fifth Street, Bristol, Tennessee 37620
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (423) 989-8000
------------------------------
Not Applicable
- --------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
<PAGE> 2
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 5. OTHER EVENTS.
On April 20, 2000, King Pharmaceuticals, Inc., a Tennessee corporation,
filed a Prospectus Supplement pursuant to Rule 424(b)(5) related to its
registration statement no. 333-95181. The Prospectus Supplement included
Supplementary Consolidated Financial Statements including a report thereon by
PricewaterhouseCoopers LLP. The related consent is included as an exhibit
hereto.
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Description
- ------- -----------
<S> <C>
23(a) Consent of PricewaterhouseCoopers LLP
</TABLE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KING PHARMACEUTICALS, INC.
Date: April 20, 2000
By: /s/ John A. A. Bellamy
John A. A. Bellamy,
Executive Vice President, Legal Affairs
and General Counsel
- 1 -
<PAGE> 1
EXHIBIT 23(A)
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the incorporation by reference in the Registration
Statement on Form S-3 (No. 333-95181) of King Pharmaceuticals, Inc. of our
report dated February 25, 2000, except for the information in Note 20 for which
the date is March 17, 2000, relating to the Supplementary Consolidated Financial
Statements, which appear in the Prospectus Supplement dated April 19, 2000. We
also consent to the reference to us under the heading "Experts" in such
Prospectus Supplement.
/s/ PricewaterhouseCoopers LLP
Greensboro, North Carolina
April 20, 2000
